Showing 2 of 10 years of data. Sign up free for 5 years of history.
View Plans2-year trend showing gross, operating, and net profit margins
Pfizer Ltd.'s net profit margin of 26.7% in FY2026 reflects excellent profitability, with operating margin at 38.2% and gross margin at 67.3%.
In FY 2026, Pfizer Ltd. posted a gross margin of 67.3%, an operating margin of 38.2%, a net margin of 26.7%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Pfizer Ltd.'s revenue grew 10.4% to 27.08B in FY2026, but net profit declined 5.9% to 7.22B — indicating margin compression.
In FY 2026, Pfizer Ltd.'s revenue grew by 10.4% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Pfizer Ltd.'s ROE of 17.2% in FY2026 indicates good shareholder returns.
In FY 2026, Pfizer Ltd. reported an ROE of 17.2%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Pfizer Ltd.'s FCF/NI ratio of 1.30x in FY2026 indicates high-quality, cash-backed earnings.
In FY 2026, Pfizer Ltd.'s free cash flow exceeded net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Pfizer Ltd.'s OCF/NI ratio of 1.34x in FY2026 indicates strong cash collection and working capital efficiency.
In FY 2026, Pfizer Ltd.'s operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Pfizer Ltd.'s current ratio of 6.06x in FY2026 indicates excessively high liquidity that may signal inefficient asset management.
In FY 2026, Pfizer Ltd. reported a current ratio of 6.06. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Pfizer Ltd.'s interest coverage ratio of 109.1x in FY2026 indicates comfortable debt servicing capacity.
In FY 2026, Pfizer Ltd. reported an interest coverage ratio of 109.1x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Pfizer Ltd.'s debt-to-equity ratio of 0.02x in FY2026 reflects a conservative, low-leverage capital structure.
In FY 2026, Pfizer Ltd. reported a debt-to-equity ratio of 0.02. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Pfizer Ltd.'s debt decreased 35.2% YoY in FY2026 — positive deleveraging improves financial flexibility.
In FY 2026, Pfizer Ltd.'s total debt decreased by 35.2% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Pfizer Ltd.'s diluted shares remained virtually unchanged in FY2026.
Over 2 years (FY2025–FY2026), diluted shares remained essentially unchanged at 45.75M.
In FY 2026, Pfizer Ltd.'s diluted shares increased by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2026